We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know
Read MoreHide Full Article
Key Takeaways
PMV Pharmaceuticals' rezatapopt achieved a 46% response rate in 76 evaluable ovarian cancer patients.
FDA discussions support an accelerated approval strategy, with an NDA submission planned for Q1 2027.
PMV Pharmaceuticals expects to raise $50.8 million through a public offering, funding operations into Q1'28.
PMV Pharmaceuticals (PMVP - Free Report) has gained nearly 19% in the past three months, primarily due to encouraging clinical data for its lead drug candidate, rezatapopt, and progress toward a potential regulatory filing in ovarian cancer.
Positive Ovarian Cancer Data Drive PMVP’s Growth
PMV Pharmaceuticals’ key growth driver is rezatapopt, an investigational precision oncology drug being developed to treat cancers harboring a specific mutation called TP53 Y220C.
In August, the company announced updated interim data from the phase II pivotal portion of the ongoing PYNNACLE study evaluating rezatapopt monotherapy in patients with platinum-resistant/refractory ovarian cancer carrying the TP53 Y220C mutation.
The study data demonstrated that treatment with rezatapopt led to an overall response rate of 46% among 76 evaluable patients, including four confirmed complete responses and 29 confirmed partial responses. The median duration of response was 10 months among patients with confirmed responses. Rezatapopt continued to show a favorable safety profile, with most treatment-related side effects being mild to moderate.
The results highlight rezatapopt’s potential to address an unmet medical need in ovarian cancer and strengthen investor confidence in the candidate’s development prospects.
Year to date, shares of PMV Pharmaceuticals have risen 21.6% against the industry’s 4.5% decline.
Image Source: Zacks Investment Research
The phase II portion of the PYNNACLE study is designed to evaluate rezatapopt across five patient cohorts covering ovarian, lung, breast and endometrial cancers, along with other solid tumors.
Following discussions with the FDA, the company remains on track to seek accelerated approval of rezatapopt for platinum-resistant or refractory ovarian cancer. The company plans to submit a new drug application (NDA) in the first quarter of 2027.
PMV Pharmaceuticals expects to present an update covering all phase II pivotal study cohorts at a medical conference in the fourth quarter of 2026, including the primary analysis results from the ovarian cancer cohort.
The upcoming data presentation could further clarify rezatapopt’s efficacy and support the company’s regulatory plans. However, the filing timeline and potential approval remain subject to clinical results, execution and regulatory review.
Public Offering Strengthens PMVP’s Financial Position
The company is strengthening its financial position to support rezatapopt’s continued development. On Aug. 31, 2026, the company priced a public offering expected to generate approximately $50.8 million in gross proceeds.
PMV Pharmaceuticals expects its existing cash resources and proceeds from the offering to fund operations into the first quarter of 2028, excluding any proceeds from warrant exercises.
The additional funding should help the company advance rezatapopt toward its planned NDA submission and support other development activities.
PMVP's Zacks Rank & Other Stocks to Consider
PMV Pharmaceuticals currently carries a Zacks Rank #2 (Buy).
Over the past 60 days, earnings per share estimates for Corcept Therapeutics have increased from $1.13 to $1.86 for 2026. Over the same period, estimates for 2027 earnings per share have risen from $2.35 to $3.48. CORT’s shares have surged 248.2% year to date.
Corcept Therapeutics’ earnings missed estimates in two of the trailing four quarters, beat in one while meet in the remaining occasion with the average surprise being 240.74%.
Over the past 60 days, earnings per share estimates for Alnylam Pharmaceuticals have decreased from $8.65 to $8.63 for 2026. Over the same period, estimates for 2027 earnings per share have narrowed from $12.13 to $12.04. ALNY’s shares have plunged 41.5% year to date.
Alnylam Pharmaceuticals’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 27.58%.
Over the past 60 days, loss per share estimates for Aldeyra Therapeuticshave narrowed from 43 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have narrowed from 22 cents to 16 cents. ALDX’s shares have plunged 82.3% year to date.
Aldeyra Therapeutics’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 29.25%.
View the Zacks #1 Rank List
Image: Bigstock
PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know
Key Takeaways
PMV Pharmaceuticals (PMVP - Free Report) has gained nearly 19% in the past three months, primarily due to encouraging clinical data for its lead drug candidate, rezatapopt, and progress toward a potential regulatory filing in ovarian cancer.
Positive Ovarian Cancer Data Drive PMVP’s Growth
PMV Pharmaceuticals’ key growth driver is rezatapopt, an investigational precision oncology drug being developed to treat cancers harboring a specific mutation called TP53 Y220C.
In August, the company announced updated interim data from the phase II pivotal portion of the ongoing PYNNACLE study evaluating rezatapopt monotherapy in patients with platinum-resistant/refractory ovarian cancer carrying the TP53 Y220C mutation.
The study data demonstrated that treatment with rezatapopt led to an overall response rate of 46% among 76 evaluable patients, including four confirmed complete responses and 29 confirmed partial responses. The median duration of response was 10 months among patients with confirmed responses. Rezatapopt continued to show a favorable safety profile, with most treatment-related side effects being mild to moderate.
The results highlight rezatapopt’s potential to address an unmet medical need in ovarian cancer and strengthen investor confidence in the candidate’s development prospects.
Year to date, shares of PMV Pharmaceuticals have risen 21.6% against the industry’s 4.5% decline.
Image Source: Zacks Investment Research
The phase II portion of the PYNNACLE study is designed to evaluate rezatapopt across five patient cohorts covering ovarian, lung, breast and endometrial cancers, along with other solid tumors.
Following discussions with the FDA, the company remains on track to seek accelerated approval of rezatapopt for platinum-resistant or refractory ovarian cancer. The company plans to submit a new drug application (NDA) in the first quarter of 2027.
PMV Pharmaceuticals expects to present an update covering all phase II pivotal study cohorts at a medical conference in the fourth quarter of 2026, including the primary analysis results from the ovarian cancer cohort.
The upcoming data presentation could further clarify rezatapopt’s efficacy and support the company’s regulatory plans. However, the filing timeline and potential approval remain subject to clinical results, execution and regulatory review.
PMV Pharmaceuticals, Inc. Price and Consensus
PMV Pharmaceuticals, Inc. price-consensus-chart | PMV Pharmaceuticals, Inc. Quote
Public Offering Strengthens PMVP’s Financial Position
The company is strengthening its financial position to support rezatapopt’s continued development. On Aug. 31, 2026, the company priced a public offering expected to generate approximately $50.8 million in gross proceeds.
PMV Pharmaceuticals expects its existing cash resources and proceeds from the offering to fund operations into the first quarter of 2028, excluding any proceeds from warrant exercises.
The additional funding should help the company advance rezatapopt toward its planned NDA submission and support other development activities.
PMVP's Zacks Rank & Other Stocks to Consider
PMV Pharmaceuticals currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the biotech sector are Amarin (AMRN - Free Report) and Corcept Therapeutics (CORT - Free Report) , currently sporting a Zacks Rank #1 (Strong Buy) each and Aldeyra Therapeutics (ALDX - Free Report) , carrying a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, earnings per share estimates for Corcept Therapeutics have increased from $1.13 to $1.86 for 2026. Over the same period, estimates for 2027 earnings per share have risen from $2.35 to $3.48. CORT’s shares have surged 248.2% year to date.
Corcept Therapeutics’ earnings missed estimates in two of the trailing four quarters, beat in one while meet in the remaining occasion with the average surprise being 240.74%.
Over the past 60 days, earnings per share estimates for Alnylam Pharmaceuticals have decreased from $8.65 to $8.63 for 2026. Over the same period, estimates for 2027 earnings per share have narrowed from $12.13 to $12.04. ALNY’s shares have plunged 41.5% year to date.
Alnylam Pharmaceuticals’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 27.58%.
Over the past 60 days, loss per share estimates for Aldeyra Therapeuticshave narrowed from 43 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have narrowed from 22 cents to 16 cents. ALDX’s shares have plunged 82.3% year to date.
Aldeyra Therapeutics’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 29.25%.